COLTENE (CLTN) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
20 Feb, 2026Executive summary
Returned to profitable growth with net sales of CHF 250.2m, up 3.1% in CHF and 6.3% in local currencies year-over-year.
EBIT margin improved to 10.7% from 8.1% last year; net profit rose to CHF 20.5m from CHF 11.9m.
Free cash flow increased to CHF 20.0m, and market share was gained despite challenging conditions.
Leadership team strengthened with new appointments in sales and marketing.
Financial highlights
Net sales grew to CHF 250.2m (+3.1% in CHF, +6.3% in local currencies) compared to prior year.
EBIT increased 36.9% to CHF 26.8m; EBIT margin at 10.7%.
Net profit surged 71.3% to CHF 20.5m; net profit margin at 8.2%.
Effective tax rate decreased to 22.7% from 25.9%.
Free cash flow reached CHF 20.0m, up from CHF 17.4m.
Outlook and guidance
Short-term outlook remains volatile due to geopolitical uncertainties.
Sales expected to grow 3-5% in local currencies for 2025; EBIT margin targeted at 11%.
Medium-term (2027) targets: annual sales growth of 3-5%, EBIT margin of 13-15%, payout ratio of about 70%.
Latest events from COLTENE
- Net profit fell 27% and EBIT margin dropped to 8.8%, with growth and margin recovery targeted for 2026.CLTN
H2 202513 Mar 2026 - Net sales dipped 3%, but higher margins and new launches support a positive H2 outlook.CLTN
H1 202420 Feb 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026 - Sales and profit dropped sharply, but recovery is expected in the second half.CLTN
H1 202520 Feb 2026